The impact of proliferation signal inhibitors on the healthcare burden of major adverse cardiac events following heart transplantation

Transplantation

Volumn 82, Issue 8 SUPPL., 2006, Pages

  Eisen, Howard ^a   Yang, Xiaolan ^b  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Cardiac allograft vasculopathy; Everolimus; Healthcare burden; Heart transplantation; MACEs; Proliferation signal inhibitors mTOR inhibitors; Sirolimus

Indexed keywords

AZATHIOPRINE; EVEROLIMUS; RAPAMYCIN;

ARTICLE; CARDIAC ALLOGRAFT VASCULOPATHY; HEALTH CARE; HEALTH CARE COST; HEART TRANSPLANTATION; HOSPITAL COST; HOSPITALIZATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTRAVASCULAR ULTRASOUND; PRIORITY JOURNAL;

EID: 33750377251     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000243152.19789.0e     Document Type: Article

References (19)

1. Taylor DO, Edwards LB, Boucek MM, et al. Registry of the International Society for Heart and Lung Transplantation: twenty-second official adult heart transplant report - 2005. J Heart Lung Transplant 2005; 24: 945.
2. Eisen HJ, Tuzcu EM, Dorent R, et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac transplant recipients. N Engl J Med 2003; 349: 847.
3. Keogh A, Richardson M, Ruygrok P, et al. Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years. A randomized clinical trial. Circulation 2004; 110: 2694.
4. Schuurman H-J, Pally C, Weckbecker G, et al. SDZ RAD inhibits cold ischemia-induced vascular remodelling. Transplant Proc 1999; 31: 1024.
5. Matsumoto Y, Hof A, Baumlin Y, Hof RP. Differential effect of cyclosporine A and SDZ RAD on neointima formation of carotid artery allografts in apolipoprotein E-deficient mice. Transplantation 2003; 76: 1166.
6. Dambrin C, Klupp J, Birsan T, et al. Sirolimus (rapamycin) monotherapy prevents graft vascular disease in nonhuman primate recipients of orthotopic aortic allografts. Circulation 2003; 107: 2369.
7. Billingham ME. Histopathology of graft coronary disease. J Heart Lung Transplant 1992; 11(Suppl): S38.
8. Mancini D, Pinney S, Burkhoff D, et al. Use of rapamycin slows progression of cardiac transplantation vasculopathy. Circulation 2003; 108: 48.
9. Viganò M, Tuzcu M, Benza R, et al. Prevention of acute rejection and allograft vasculopathy by everolimus in cardiac transplant recipients: a 24-month analysis. J Heart Lung Transplant 2006; in press.
10. Sergovia J, Alonso-Pulpón L, Ortiz P, et al. Rapastat: evaluation of the role of oral sirolimus in the treatment of established graft vessel disease. A prospective, randomized intravascular ultrasound study. J Heart Lung Transplant 2004; 23(Suppl 2): S51.
11. Kobashigawa J. What is the optimal prophylaxis for treatment of cardiac allograft vasculopathy? Curr Control Trials Cardiovasc Med 2000; 1: 166.
12. Moien-Afshari F, McManus BM, Laher I. Immunosuppression and transplant vascular disease: benefits and adverse effects. Pharmacol Ther 2003; 100: 141.
13. Kobashigawa JA, Tobis JM, Starling RC, et al. Multicenter intravascular ultrasound validation study among heart transplant recipients: outcomes after five years. J Am Coll Cardiol 2005; 45: 1532.
14. Mehra MR, Ventura HO, Uber PA, Scott RL, Park MH. Is all intimal proliferation created equal in cardiac allograft vasculopathy? The quantity - quality paradox. J Heart Lung Transplant 2003; 22: 118.
15. Mehra MR, Uber PA. TOR inhibitors and cardiac allograft vasculopathy: is inhibition of intimal thickening an adequate surrogate of benefit? J Heart Lung Transplant 2003; 22: 501.
16. US Healthcare cost and Utilization Project 2003 (http://hcup.ahrq.gov).
17. Eisen H, Starling RC, Kobashigawa J. Incidence of MACE and economic burden in de novo heart transplant patients: a 4 year comparison of everolimus and azathioprine. Transpl Int 2005; 18 (Suppl 1): PO111.
18. Kobashigawa JA, Tobis JM, Mentzer RM, et al. Mycophenolate mofetil reduces intimal thickness by intravascular ultrasound after heart transplant: reanalysis of the multicenter trial. Am J Transplant 2006; 6: 993.
19. Eisen HJ, Kobashigawa J, Keogh A, et al. Three-year results of a randomized, double-blind, controlled trial of mycophenolate mofetil versus azathioprine in cardiac transplant recipients. J Heart Lung Transplant 2005; 24: 517.